Show Notes
OpenAI and Thrive Holdings built Tax AI, a Codex-powered agent that helps prepare complex tax returns while preserving evidence for accountant review.
In this episode, Corey and Grant talk with OpenAI’s John de Wasseige and Arthur Fernandes Araujo about how expert corrections become structured signals, how Codex turns repeated failures into evals and scoped engineering tasks, and why the best AI deployments still need humans close to the work.
They also dig into what this pattern could mean for bookkeeping, audits, IT help desks, and other expert workflows where the system can measure what “right” looks like.
Relevant links: OpenAI Tax AI case study: https://openai.com/index/building-self-improving-tax-agents-with-codex/ OpenAI Codex: https://openai.com/codex/ Harness engineering: https://openai.com/index/harness-engineering/ Thrive Holdings: https://www.thriveholdings.com/ Crete: https://www.cretepa.com/
Subscribe to The Neuron newsletter: https://theneuron.ai
More from The Neuron: AI Explained
Neurosurgeon-scientists Alex Ksendzovsky and Jon Pomeraniec explain how The Biological Computing Company uses living neurons as a research platform for AI. Their team grows roughly 150,000 cells on a 4,096-electrode array, sends in patterns such as handwritten digits, records how the neurons respond, and models useful computational behaviors in software. They say those neuron-inspired techniques are already helping GPU-based video-generation systems run about 5x faster with roughly 80% lower inference cost, while their longer-term work explores robots, world models, and real-time biological compute.
OpenAI just dropped 20+ announcements at DevDay 2026, so... yeah, we have some things to talk about. 😺
Runway co-founder Anastasis Germanidis explains Solaris, an “interface world model” that generates software frame by frame instead of rendering a traditional interface from HTML and CSS.
OpenAI DevDay 2026 is here, and we’re hosting a watch party to watch the keynote LIVE.
Corey and Grant sit down with Mammoth Biosciences co-founder and CEO Dr. Trevor Martin to explain how CRISPR is moving from a laboratory tool toward one-time medicines.